Similar articles for PMID: 37097652

Year	Number of Results
1996	1
2000	1
2010	2
2011	1
2015	1
2016	9
2017	7
2018	7
2019	11
2020	11
2021	13
2022	26
2023	15
2024	9
2025	1

1

Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers.

Ueda T, Tsubamoto H, Takimoto Y, Isono-Taniguchi R, Narita S, Nakagawa K, Wakimoto YU, Nishimura Y, Muroi Y, Nagahashi M, Hirota S, Sawai H, Shibahara H. Ueda T, et al. Anticancer Res. 2023 May;43(5):2091-2101. doi: 10.21873/anticanres.16370. Anticancer Res. 2023. PMID: 37097652

2

[Abnormalities of DNA repair and gynecological cancers].

Auguste A, Leary A. Auguste A, et al. Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18. Bull Cancer. 2017. PMID: 29054544 Review. French.

3

New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.

Liu FW, Tewari KS. Liu FW, et al. Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9. Curr Treat Options Oncol. 2016. PMID: 26931795 Free PMC article. Review.

4

Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.

Goebel EA, Kerkhof J, Dzyubak O, McLachlin CM, McGee J, Sadikovic B. Goebel EA, et al. Genes (Basel). 2022 Aug 6;13(8):1398. doi: 10.3390/genes13081398. Genes (Basel). 2022. PMID: 36011309 Free PMC article.

5

Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.

Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G. Sivakumaran T, et al. Int J Gynecol Cancer. 2022 Jul 4;32(7):906-912. doi: 10.1136/ijgc-2021-003009. Int J Gynecol Cancer. 2022. PMID: 35321889 Free article.

6

Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.

Garg K, Karnezis AN, Rabban JT. Garg K, et al. Pathology. 2018 Feb;50(2):238-256. doi: 10.1016/j.pathol.2017.10.009. Epub 2018 Jan 17. Pathology. 2018. PMID: 29373116 Review.

7

DNA damage response as a therapeutic target in gynecological cancers.

Leary A, Auguste A, Mesnage S. Leary A, et al. Curr Opin Oncol. 2016 Sep;28(5):404-11. doi: 10.1097/CCO.0000000000000320. Curr Opin Oncol. 2016. PMID: 27455135

8

Inherited gynaecological cancers.

George A. George A. Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465. Curr Opin Oncol. 2018. PMID: 30036195 Review.

9

The role of PARP inhibitors in gastrointestinal cancers.

Hanna D, Chopra N, Hochhauser D, Khan K. Hanna D, et al. Crit Rev Oncol Hematol. 2022 Mar;171:103621. doi: 10.1016/j.critrevonc.2022.103621. Epub 2022 Feb 3. Crit Rev Oncol Hematol. 2022. PMID: 35124199 Review.

10

U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.

Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. Dottino JA, et al. Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171. Obstet Gynecol. 2019. PMID: 30870286 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 37097652

101 results

Results by year